Viridian Therapeutics, Inc. (VRDN)
30.87
+0.39
(+1.28%)
USD |
NASDAQ |
Nov 13, 16:00
31.02
+0.15
(+0.49%)
After-Hours: 07:57
Viridian Therapeutics Net Income (Quarterly) : -101.21M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -101.21M |
| June 30, 2026 | -127.12M |
| March 31, 2026 | -104.90M |
| December 31, 2025 | -101.98M |
| September 30, 2025 | -34.60M |
| June 30, 2025 | -100.74M |
| March 31, 2025 | -86.91M |
| December 31, 2024 | -64.65M |
| September 30, 2024 | -76.69M |
| June 30, 2024 | -64.99M |
| March 31, 2024 | -48.54M |
| December 31, 2023 | -66.86M |
| September 30, 2023 | -47.66M |
| June 30, 2023 | -55.06M |
| March 31, 2023 | -68.15M |
| December 31, 2022 | -45.78M |
| September 30, 2022 | -28.90M |
| June 30, 2022 | -29.49M |
| March 31, 2022 | -25.69M |
| December 31, 2021 | -28.95M |
| September 30, 2021 | -14.04M |
| June 30, 2021 | -17.96M |
| March 31, 2021 | -18.46M |
| December 31, 2020 | -90.74M |
| September 30, 2020 | -5.494M |
| Date | Value |
|---|---|
| June 30, 2020 | -6.435M |
| March 31, 2020 | -8.044M |
| December 31, 2019 | -10.12M |
| September 30, 2019 | -11.23M |
| June 30, 2019 | -8.896M |
| March 31, 2019 | -11.63M |
| December 31, 2018 | -10.32M |
| September 30, 2018 | -9.011M |
| June 30, 2018 | -8.714M |
| March 31, 2018 | -4.661M |
| December 31, 2017 | -6.386M |
| September 30, 2017 | -5.834M |
| June 30, 2017 | -7.312M |
| March 31, 2017 | -6.985M |
| December 31, 2016 | -5.986M |
| September 30, 2016 | -4.166M |
| June 30, 2016 | -2.507M |
| March 31, 2016 | -2.758M |
| December 31, 2015 | -2.98M |
| September 30, 2015 | -3.152M |
| June 30, 2015 | -2.562M |
| March 31, 2015 | -2.634M |
| December 31, 2014 | -2.258M |
| September 30, 2014 | -1.637M |
| June 30, 2014 | -3.289M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Travere Therapeutics, Inc. | -61.04M |
| Arrowhead Pharmaceuticals, Inc. | -428.88M |
| Vertex Pharmaceuticals, Inc. | 653.60M |
| TG Therapeutics, Inc. | 55.46M |
| ACADIA Pharmaceuticals, Inc. | 53.52M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 25.75M |
| Total Expenses (Quarterly) | 126.96M |
| EPS Diluted (Quarterly) | -0.8924 |
| Enterprise Value | 2.889B |
| Gross Profit Margin (Quarterly) | 92.74% |
| Profit Margin (Quarterly) | -393.0% |
| Earnings Yield | -13.53% |
| Normalized Earnings Yield | -13.70 |